DK1923702T3 - Hidtil ukendte midler og fremgangsmåder til behandling af høretab og fantomhørelse - Google Patents

Hidtil ukendte midler og fremgangsmåder til behandling af høretab og fantomhørelse

Info

Publication number
DK1923702T3
DK1923702T3 DK08004076.9T DK08004076T DK1923702T3 DK 1923702 T3 DK1923702 T3 DK 1923702T3 DK 08004076 T DK08004076 T DK 08004076T DK 1923702 T3 DK1923702 T3 DK 1923702T3
Authority
DK
Denmark
Prior art keywords
fragment
seq
nucleic acid
protein
sequence
Prior art date
Application number
DK08004076.9T
Other languages
English (en)
Inventor
Karl-Heinz Krause
Botond Banfi
Original Assignee
Univ Geneve
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Geneve filed Critical Univ Geneve
Application granted granted Critical
Publication of DK1923702T3 publication Critical patent/DK1923702T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90209—Oxidoreductases (1.) acting on NADH or NADPH (1.6), e.g. those with a heme protein as acceptor (1.6.2) (general), Cytochrome-b5 reductase (1.6.2.2) or NADPH-cytochrome P450 reductase (1.6.2.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/14—Disorders of ear, nose or throat

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
DK08004076.9T 2004-06-04 2005-06-06 Hidtil ukendte midler og fremgangsmåder til behandling af høretab og fantomhørelse DK1923702T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04013266A EP1602926A1 (en) 2004-06-04 2004-06-04 Novel means and methods for the treatment of hearing loss and phantom hearing
EP05750543A EP1766390A2 (en) 2004-06-04 2005-06-06 Novel means and methods for the treatment of hearing loss and phantom hearing

Publications (1)

Publication Number Publication Date
DK1923702T3 true DK1923702T3 (da) 2010-10-25

Family

ID=34925261

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08004076.9T DK1923702T3 (da) 2004-06-04 2005-06-06 Hidtil ukendte midler og fremgangsmåder til behandling af høretab og fantomhørelse

Country Status (7)

Country Link
US (3) US8088359B2 (da)
EP (3) EP1602926A1 (da)
AT (1) ATE477485T1 (da)
DE (1) DE602005022948D1 (da)
DK (1) DK1923702T3 (da)
ES (1) ES2349894T3 (da)
WO (1) WO2005119251A2 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4969002B2 (ja) 1999-06-08 2012-07-04 ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン ｒＡＡＶ形質導入を増加するための化合物および方法
US8241622B2 (en) 2001-07-13 2012-08-14 University Of Iowa Research Foundation Adeno-associated virus vectors with intravector heterologous terminal palindromic sequences
WO2004090145A2 (en) 2003-03-31 2004-10-21 University Of Iowa Research Foundation Compounds and methods to enhance raav transduction
JP2009521928A (ja) * 2005-12-30 2009-06-11 ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン 神経細胞変性疾患の治療に有用な化合物を特定する方法
US7825099B2 (en) 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
EP2019964A2 (en) * 2006-04-28 2009-02-04 University of Iowa Research Foundation Methods and compounds to modulate parvovirus transduction of mammalian cells or to alter virus infection. method to identify a viral receptor or co-receptor
JP2010507387A (ja) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のｓｉＲＮＡおよびその使用方法
WO2009044294A2 (en) * 2007-06-15 2009-04-09 Université De Geneve Means and methods for the treatment of cataract and presbyopia
SI2170403T1 (sl) 2007-06-27 2014-07-31 Quark Pharmaceuticals, Inc. Sestavki in postopki za inhibicijo ekspresije pro-apoptotskih genov
WO2009023025A1 (en) * 2007-08-13 2009-02-19 Board Of Trustees Of Southern Illinois University Methods for treatment and prevention of ototoxicity by sirna
CN101815521B (zh) 2007-10-03 2014-12-10 夸克制药公司 新siRNA结构
EP3381445B1 (en) * 2007-11-15 2023-10-25 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration
EP2293800B1 (en) 2008-06-06 2016-10-05 Quark Pharmaceuticals, Inc. Compositions and methods for treatment of ear disorders
US20110288155A1 (en) 2008-12-18 2011-11-24 Elena Feinstein Sirna compounds and methods of use thereof
CN103917647B (zh) 2011-11-03 2020-07-10 夸克制药公司 用于神经保护的方法和组合物
EP2802657B1 (en) 2012-01-12 2018-05-02 Quark Pharmaceuticals, Inc. Combination therapy for treating hearing and balance disorders
US11702672B2 (en) 2016-02-08 2023-07-18 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
MX2018010842A (es) 2016-03-07 2019-07-04 Univ Iowa Res Found Expresion mediada por el virus adeno-asociado (aav) usando un promotor y pontenciador sintetico.
US11142775B2 (en) 2017-01-13 2021-10-12 University Of Iowa Research Foundation Bocaparvovirus small noncoding RNA and uses thereof
US20220054640A1 (en) * 2018-12-11 2022-02-24 Decibel Therapeutics, Inc. Compositions and methods for the delivery of therapeutic agents across the round window membrane

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4670388A (en) 1982-12-30 1987-06-02 Carnegie Institution Of Washington Method of incorporating DNA into genome of drosophila
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
DE3852539T3 (de) 1987-12-15 2005-08-04 Gene Shears Pty. Ltd. Ribozyme.
KR900700134A (ko) 1988-04-15 1990-08-11 원본미기재 Il-2 수용체-특이적 키메릭 항체
CA1340323C (en) 1988-09-20 1999-01-19 Arnold E. Hampel Rna catalyst for cleaving specific rna sequences
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
GB9308271D0 (en) 1993-04-21 1993-06-02 Univ Edinburgh Method of isolating and/or enriching and/or selectively propagating pluripotential animal cells and animals for use in said method
WO1994029469A2 (en) 1993-06-07 1994-12-22 Vical Incorporated Plasmids suitable for gene therapy
KR100654645B1 (ko) 1995-04-27 2007-04-04 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU723325B2 (en) 1995-06-23 2000-08-24 President And Fellows Of Harvard College Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
US5763496A (en) 1995-11-27 1998-06-09 The Research Foundation Of State University Of New York Prevention of atherosclerosis using NADPH oxidase inhibitors
WO2000028031A2 (en) * 1998-11-10 2000-05-18 Emory University Mitogenic regulators
US6242473B1 (en) 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
WO2002030453A1 (en) 2000-10-12 2002-04-18 Beth Israel Deaconess Medical Center, Inc. Methods of inhibiting angiogenesis using nadph oxidase inhibitors
CA2429376A1 (en) * 2000-11-16 2002-10-17 Emory University Mitogenic oxygenase regulators
ES2728168T3 (es) * 2000-12-01 2019-10-22 Max Planck Gesellschaft Moléculas pequeñas de ARN que median en la interferencia de ARN
EP1361885B1 (en) * 2001-02-20 2008-04-16 GTX Pharmaceuticals GmbH Use of gamma-gt inhibitors for the treatment of chronic degenerative diseases
US6489149B1 (en) 2001-03-29 2002-12-03 Pe Corporation (Ny) Isolated human NADPH oxidase, nucleic acid molecules encoding said proteins, and uses thereof
CN1269475C (zh) * 2002-03-25 2006-08-16 科学工业研究委员会 反式－二十四－15－碳烯酸和夹竹桃麻素的协同组合物及其应用
AU2003224549A1 (en) 2002-04-17 2003-10-27 Biovitrum Ab Nad)p)h oxidase inhibitors for increased glucose uptake and treatment of type ii diabetes
JP4578235B2 (ja) 2002-05-13 2010-11-10 アレクシス・アクチボラゲット 自己免疫状態およびｎａｄｐｈオキシダーゼ欠損
WO2004007686A2 (en) * 2002-07-12 2004-01-22 Emory University Methods and transgenic mouse model for identifying and modulating factors involved in the production of reactive oxygen intermediates
US7029673B2 (en) * 2002-07-16 2006-04-18 Emory University Regulatory protein for Nox enzymes
AU2003295600A1 (en) * 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
US7825099B2 (en) * 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
JP2010507387A (ja) * 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のｓｉＲＮＡおよびその使用方法
WO2008152636A2 (en) * 2007-06-15 2008-12-18 Quark Pharmaceuticals, Inc. Compositions and methods for inhibiting nadph oxidase expression

Also Published As

Publication number Publication date
US9650635B2 (en) 2017-05-16
DE602005022948D1 (de) 2010-09-23
US20120252868A1 (en) 2012-10-04
ES2349894T3 (es) 2011-01-12
WO2005119251A3 (en) 2006-05-26
US8722639B2 (en) 2014-05-13
EP1602926A1 (en) 2005-12-07
EP1923702B1 (en) 2010-08-11
US20140356457A1 (en) 2014-12-04
US20090263323A1 (en) 2009-10-22
ATE477485T1 (de) 2010-08-15
EP1766390A2 (en) 2007-03-28
WO2005119251A2 (en) 2005-12-15
EP1923702A2 (en) 2008-05-21
US8088359B2 (en) 2012-01-03
EP1923702A3 (en) 2008-08-06

Similar Documents

Publication Publication Date Title
DK1923702T3 (da) Hidtil ukendte midler og fremgangsmåder til behandling af høretab og fantomhørelse
CY1112893T1 (el) Πρωτεϊνες δεσμευομενες με il-18
DE602005024274D1 (de) Als aurora-kinase-inhibitoren nutzbare thienopyrimidine
TW200716647A (en) Synthesis of (R)-N-methylnaltrexone
DK1899378T3 (da) IL-1 beta-bindende antistoffer og fragmenter deraf
EA200601313A1 (ru) Варианты участка f
HK1103746A1 (en) Antibodies to erythropoietin receptor and uses thereof
EP2374451A3 (en) Histone deacetylase inhibitors (HDAC) that correct protein misfolding and uses thereof
DK1615992T3 (da) Prionproteinbindende materialer og fremgangsmåder til anvendelse
ATE465173T1 (de) Verändertes vp-1capsidprotein von parvovirus b19
DE602007009954D1 (de) Verfahren zur identifizierung von polypeptid-targets
WO2008053478A3 (en) Compositions and methods for inhibiting hiv-1 replication and integrase activity
DK1512015T3 (da) Fremgangsmåder til forbedring af bindingsegenskaber hos et molekyle
DE602006019710D1 (de) Magnesiumsalze von hmg-coa-reduktase-hemmern
CY1107367T1 (el) Σαρωση για πεπτιδια που αναστελουν προσδεση της pp1c στις πρωτεϊνες bcl-2, bcl-xl και bcl-w
CO6382184A2 (es) Proteinas fijadoras de receptores de interleukinas-21
ATE352566T1 (de) Verfahren zur reinigung von interleukin-4 und seinen muteinen
WO2009048658A3 (en) Optimized dengue virus entry inhibitory peptide (dn81)
ATE498016T1 (de) Transposon-system zur gezielten integration
WO2002022661A3 (en) NOVEL PDEs AND USES THEREOF
WO2006024041A3 (en) Monomeric and dimeric fluorescent protein variants and methods for making same
DE602004021567D1 (de) Antikörper gegen tumorspezifisches antigen als ziel
EP1677739A4 (en) METHODS FOR IDENTIFYING AGENTS THAT INHIBIT THE GROWTH OF CANCER CELLS
WO2007014951A3 (en) Methods for the screening of antibacterial substances
WO2007020405A3 (en) Integrin i-domain binding peptides